Mechanism · Research Data · Protocols · Compound Information
GHK-Cu, or Copper Tripeptide-1, is a naturally occurring human copper complex discovered in 1973 by Dr. Loren Pickart. It is an oligopeptide with the amino acid sequence glycyl-L-histidyl-L-lysine that readily complexes with copper(II) ions. This peptide is extensively studied across various biological systems, primarily for its roles in tissue regeneration, wound healing, anti-inflammatory processes, and antioxidant defence mechanisms.
Researchers are investigating GHK-Cu for its potential to modulate gene expression, stimulate collagen and elastin production, and support cellular repair pathways. Its broad spectrum of observed biological activities positions it as a significant subject in regenerative medicine, dermatology, and age-related research. This guide is for educational and research purposes only. Not medical advice, and the compound is not approved for human therapeutic use.
The following table summarises the current types of evidence available for GHK-Cu in scientific literature.
| Evidence Type | Status |
|---|---|
| Human Randomised Controlled Trials (RCTs) | ✔ (Primarily for topical applications in skin/hair research) |
| Observational Studies | ✔ (Associated with topical use and anecdotal reports in research settings) |
| Animal Studies | ✔ (Extensive research across numerous species and models) |
| In Vitro Studies | ✔ (Abundant research on cell cultures and biochemical assays) |
| Regulatory Approval for Human Therapeutic Use | ✗ (Not approved by major regulatory bodies like HPRA, FDA, EMA) |
GHK-Cu exerts its diverse biological effects through several complex mechanisms. As a copper-binding peptide, it delivers copper ions to cells, which are crucial cofactors for numerous enzymatic reactions involved in processes like collagen cross-linking (via lysyl oxidase) and superoxide dismutase activity (an antioxidant enzyme). Beyond its role as a copper carrier, GHK-Cu itself possesses inherent signalling properties.
Research indicates that GHK-Cu can directly modulate gene expression, influencing the upregulation of genes involved in tissue repair and extracellular matrix remodelling, such as collagen, elastin, proteoglycans, and glycosaminoglycans. It has also been observed to downregulate genes associated with inflammation and fibrosis, demonstrating an anti-inflammatory effect. Furthermore, GHK-Cu is investigated for its ability to stimulate the proliferation and migration of fibroblasts and keratinocytes, essential cells in wound healing and skin regeneration, and to promote angiogenesis (new blood vessel formation) via pathways involving VEGF and other growth factors.
Its antioxidant capacity is partly attributed to its ability to scavenge reactive oxygen species and has been observed to support the expression of antioxidant enzymes. GHK-Cu's interaction with specific cell surface receptors or intracellular pathways is still an active area of research, but its multifaceted impact on cellular function positions it as a potent regenerative agent.
Research suggests that GHK-Cu promotes the synthesis of collagen, elastin, and glycosaminoglycans, which are vital components of the extracellular matrix. In topical human studies and in vitro models, it has been observed to has been studied for potential improvements in skin elasticity, firmness, and reduce the appearance of fine lines and wrinkles. Animal studies have further supported its role in enhancing dermal repair and remodelling.
GHK-Cu has been extensively investigated for its profound effects on wound healing. In numerous animal models (e.g., rats, mice, pigs), studies have shown that GHK-Cu accelerates wound closure, has been studied for potential improvements in wound contraction, and has been observed to support the formation of granulation tissue. Its observed ability to stimulate angiogenesis and reduce inflammation contributes significantly to these reparative processes.
In various research models, GHK-Cu has been observed to stimulate hair follicle enlargement and hair growth. Studies using both in vitro human hair follicle cultures and animal models (e.g., mice) suggest that it can promote the proliferation of dermal papilla cells and extend the anagen phase of the hair cycle, making it a subject of interest in research related to alopecia.
Research indicates that GHK-Cu possesses significant anti-inflammatory and antioxidant capabilities. It has been shown in in vitro and animal models to reduce inflammatory cytokine levels (e.g., TNF-alpha, IL-6) and scavenge free radicals, thereby protecting tissues from oxidative damage. These properties are thought to contribute to its observed benefits in tissue repair and neuroprotection.
Emerging research, primarily from in vitro and animal models, suggests GHK-Cu may have neuroprotective effects. It has been investigated for its potential to reduce neuroinflammation, protect neurons from oxidative stress, and promote nerve regeneration. Some studies explore its relevance in models of neurodegenerative conditions, though this area requires further extensive human research.
| Study / Model | Reported Effect |
|---|---|
| Human Skin Biopsies (Topical Application) | Increased collagen I mRNA levels by ~110% and elastin mRNA levels by ~130% over placebo. |
| Rat Excisional Wound Model | Accelerated wound closure by up to 30% compared to controls; enhanced angiogenesis (increased capillary density). |
| Human Hair Follicle Organ Culture | Promoted hair shaft elongation and increased proliferation of dermal papilla cells. |
| Mouse Model of Inflammatory Bowel Disease | Reduced inflammatory markers (e.g., MPO activity) and ameliorated colonic tissue damage. |
| In Vitro Human Fibroblast Culture | Stimulated fibroblast proliferation by ~70% and enhanced production of matrix metalloproteinases (MMPs) involved in tissue remodelling. |
| Diabetic Rat Wound Model | Significantly improved wound healing rates and collagen deposition in compromised wounds. |
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
These protocols are derived from experimental research models and are provided for informational context only. They are not dosing recommendations or clinical guidelines.
| Protocol | Dose (for research context) | Duration (experimental) | Frequency (experimental) | Research Context |
|---|---|---|---|---|
| Low-Range Research Protocol | 1mg per application/administration | 4-6 weeks | Daily or every other day | Topical skin regeneration, localized tissue repair models. |
| Standard Research Protocol | 2-3mg per application/administration | 8-12 weeks | Daily or 3-4 times per week | Systemic regenerative studies, moderate wound healing, hair growth models. |
| Advanced Research Protocol | 4-5mg per application/administration | 12+ weeks | Daily | Intensive tissue remodelling, severe injury repair models (experimental). |
Disclaimer: These are experimental research protocols only and are not dosing recommendations for human use. GHK-Cu is not approved for human therapeutic use.
Based on available published research, GHK-Cu is generally considered to have a favourable safety profile in experimental settings. Reported adverse observations in studies primarily include:
No severe adverse events have been consistently reported in the available scientific literature for GHK-Cu in research contexts. Researchers should always conduct thorough risk assessments.
Peptide dosing calculator, cycle planner, macro guide and more. No signup required.
Explore Free Tools